WHAT IS THE IMPACT OF *IL12B*+1188 SINGLE NUCLEOTIDE POLYMORPHISM ON IL-12 SERUM LEVEL of MULTIPLE SCLEROSIS IRAQI PATIENTS?

Milad A. Al-Nasiri, Ehab D. Salman, Ali H. Ad’hiab and Sarmad A. Al-Mashtah.

1. Sera and Vaccine Institute, Ministry of Health, Baghdad, Iraq.
2. Biotechnology Department, College of Science, University of Baghdad, Baghdad, Iraq.
3. Tropical-Biological Research Unit, College of Science, University of Baghdad, Baghdad, Iraq.
4. Baghdad Teaching Hospital, Ministry of Health, Baghdad, Iraq.

**Abstract**

Multiple sclerosis (MS) is a chronic neurodegenerative disease that results from interaction between genetic, epigenetic, and environmental factors, and affects especially young adults. Serum level and single nucleotide polymorphism (SNP) of Interleukin-12 (IL-12) were determined in 68 relapsing-remitting MS Iraqi patients and 20 healthy individuals, matched patients for ethnicity, age and gender. The patients were distributed into IFNβ pre- and post-medicated patients, in addition, extended disability status scale (EDSS) was also applied as a parameter for distribution. The results indicated that there were significant differences in serum levels of IL-12 among the three investigated groups; pre- and post-medicated patients and controls (35.9 ± 1.6 vs. 29.5 ± 2.4 vs. 22.7 ± 2.9 pg/ml, respectively). However, there was no significant effect of EDSS on the level of IL-12 in pre- and post-medicated patients. *IL12B* gene SNP at position +1188 was presented with three genotypes (AA, AC and CC), which showed a significant difference between the observed and expected genotype frequencies (p ≤ 0.01) in patients, while a good agreement with Hardy-Weinberg equilibrium was observed in controls. However, there was no significant variation between patients and controls in the distribution of *IL12B*+1188 allele and genotype frequencies; although CC genotype was observed with a frequency of 17.9% in MS patients, while none of the controls possessed such genotype, and the odds ratio of such difference was 9.23. A significant impact of *IL12B*+1188 SNP on IL-12 serum level was recorded in MS patients carrying CC and AC genotypes (27.1 ± 3.1 vs. 35.9 ± 2.4 pg/ml, respectively), while no such impact was observed in controls.

**Introduction:**

Multiple sclerosis (MS) is a neurodegenerative autoimmune disease that causes axon demyelination leading to plaque formation in white matter of central nervous system (Shirani and Tremlett, 2010). Genetic, epigenetic and environmental factors were suggested to trigger MS episodes, in which immunological factors are also involved; especially cytokines (Fragoso *et al.,* 2014; Fukaura, 2014; van den Elsena *et al.,* 2014).

**Corresponding Author:** Meelad A. Al-Nasiri.

Address: Sera and Vaccine Institute, Ministry of Health, Baghdad, Iraq.
IL-12 is one of these cytokines, compoes of two subunits; p35 and p40. It regulates both innate and adaptive immune responses, and produced mainly by phagocytes and dendritic cells upon infection with various pathogens. Such production results in stimulating natural killer (NK) cells and cytotoxic T-lymphocytes (CTLS) to secret IFN-γ (Xu et al., 2010). Additionally, IL-12 activates T-cell differentiation and antibody production by B-cell, increases the cytotoxicity and differentiation of naïve CD4+ T-cells to Th1 cells, and enhances the expression of MHC II and adhesion molecules on Th1 cells (van Wanrooij et al., 2012).

**IL12B** gene is located on chromosome 5q31-33, and encodes the p40 subunit that is responsible for proliferation and differentiation of Th1 cells through enhancing IFN-γ production. The gene has been suggested to have relevance to many autoimmune diseases including MS (Zhang et al., 2015). **IL12B** A1188 SNP has been suggested to have a significant role in MS predisposition (Shokrgozar et al., 2009), but a recent meta-analysis by Huang et al. (2016) failed to confirm such finding in Caucasian and some Asian patients. Accordingly, the present investigation aimed to determine the role of IL-12 in pathogenesis of MS in Iraqi patients in terms of serum level and genetic polymorphism of **IL12B** at locus +1188.

**Materials and methods:**

**Patients:**

Sixty eight Iraqi Arab Muslim patients were diagnosed as relapsing-remitting multiple sclerosis (RRMS) patients by physicians according to McDonald criteria 2010 revision (Milo and Miller, 2014) at Multiple Sclerosis Clinic (Baghdad Teaching Hospital). The patients were distributed as: 30 pre-medicated patients (did not receive the immunomodulatory drug IFNβ or corticosteroids) and 38 patients received IFNβ (post-medicated). The post – medicated patients were treated with 8MI4 dosage of IFNβ every other day administered subcutaneously (SC). The patients were also distributed according to the extended disability status scale (EDSS); < 3 and ≥ 3. Scores from 0 to less than 3 (< 3) means that the patient is fully ambulant, while score equals or higher than 3 (≥ 3) is given to patients with moderate to high disability. Some detailed informations about patients are given in table 1.

**Controls:**

The controls (20 subjects) were obtained from Teaching Laboratories of Medical City personnel who were not receiving any non-steroidal anti-inflammatory drugs (NSAIDs) for at least 48 hours, non-smokers, and had no history of any autoimmune disease, and were apparently healthy. They were Iraqis and distributed as 5 males (age mean: 37.0 ± 4.9 years) and 15 females (age mean: 34.3 ± 2.2 years).

| Characteristics         | Multiple Sclerosis Patients (No. = 68) |                  |                  |
|-------------------------|--------------------------------------|------------------|------------------|
|                         | Pre-medicated (No. = 30)             | Post-medicated (No. = 38) |
|                         | Males (No. = 10)                     | Females (No. = 20)* | Males (No. = 13) | Females (No. = 25)** |
| Age Mean ± SE (Years)   | 34.9 ± 3.1                          | 33.3 ± 2.3       | 34.5 ± 2.2       | 36.1 ± 2.1           |
| Extended Disability     | < 3                                  | 7                | 7                | 9                  | 17                |
| Score                   | ≥ 3                                  | 3                | 10               | 4                  | 7                 |

*EDSS was missing from three cases; **EDSS was missing from one case

**Sample collection:**

The blood (5 ml) of 68 MS patients and 20 controls was withdrawn into two kinds of tubes: plain and K₂- EDTA tubes. The plain tube blood was left to clot, and then centrifuged at 3000 rpm and the serum was collected and frozen at -20°C until assessment of IL-12 serum level. The K₂-EDTA blood was frozen at -20°C until isolation of DNA for **IL12B** A1188 SNP determination.

**Measurement of IL-12 Serum Level:**

Serum level of IL-12 was assessed in sera of MS patients and controls by means of ELISA (enzyme linked immunosorbsent assay) principles. The assessment was carried out by using mini-ELISA kit that was produced by PeproTech Company (U.K.), and the manufacturer instructions were followed. The sample results were calculated by interpolation from a standard curve that was performed in the same assay as that for the samples by using standard curve fitting equation for IL-12. The equation and drawing of the standard curve were carried out using Microsoft Excel 2010.
DNA isolation:
Genomic DNA was isolated from frozen EDTA blood by using ReliaPrep™ gDNA MiniPrep System Kit, U.S.A. The concentration and purity of the DNA samples were estimated by using NanoDrop technology at optical densities of 260/280 nm wavelength.

\textbf{IL12B}+1188 Genotyping:
Single nucleotide polymorphism for \textit{IL12B}+1188 gene was analysed by using Cytokine CTS-SSP-PCR Tray kit provided by Collaborative Transplant Study (CTS) for genotyping of cytokine polymorphisms, Heidelberg, Germany. The genotyping was performed according to the instruction supplied with the kit, and then agarose gel electrophoresis was performed by using 2% agarose at 170 V for 25 minutes. The amplification signal was identified positive or negative through UV transilluminator (312nm) and the results were interpreted according to the manual supplied with kit.

Statistical analysis:
Serum level of IL-12 was statistically analyzed using SPSS (Statistical Package for Social Sciences) version 13. The data were given as mean ± standard error (S.E.), and differences between means were assessed by ANOVA (Analysis of Variance), followed by LSD (Least Significant Difference) or Duncan test. A Pearson Chi-square was also used to test the significant differences between EDSS within patients’ group.

Allele frequencies of \textit{IL12B}+1188 gene was calculated by direct gene counting method, while significant departure from Hardy-Weinberg equilibrium (HWE) was estimated using online H-W calculator for two alleles (http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-2-alleles). Allele and genotype of \textit{IL12B}+1188 were presented as percentage frequencies, and significant differences between their distributions in MS patients and controls were assessed by two-tailed Fisher’s exact probability (\(p\)). In addition, odds ratio (OR), etiological fraction (EF) and preventive fraction (PF) were also estimated to define the association between alleles and genotypes with the disease (Ad’hiah, 1990; Abramson, 2011).

Results and Discussion:
\textbf{IL-12 serum level:}
Pre-medicated MS patients showed the highest level of IL-12 (35.9 ± 1.6 pg/ml), followed by post-medicated patients (29.5 ± 2.4 pg/ml), and finally controls (22.7 ± 2.9 pg/ml), and these differences were significant. However, there was no significant effect of EDSS on the level of IL-12 between pre- and post-medicated patients (Table 2).

\textbf{Table 2:} Serum level mean of IL-12 in pre-medicated and post-medicated multiple sclerosis patients and controls.

| Groups      | IL-12 Serum Level Mean ± S.E. (pg/ml) |
|-------------|---------------------------------------|
|             | Patients (No. = 68)                   | Controls (No. = 20) |
|             | Pre-medicated (No. = 30)              | Post-medicated (No. = 38) |
| Total       | 35.9 ± 1.6\(^{A}\)                   | 29.5 ± 2.4\(^{B}\) |
| EDSS        | 22.7 ± 2.9\(^{C}\)                   | 22.7 ± 2.9\(^{A}\) |
| < 3         | 35.7 ± 2.1\(^{A}\)                   | 28.8 ± 2.7\(^{A}\) |
| ≥ 3         | 37.3 ± 2.6\(^{A}\)                   | 32.6 ± 5.1\(^{A}\) |
| \(p\) ≤     | Not significant                       | Not significant |

\(^{A,B,C}\): Probability of difference between means of extended disability status scale groups.

\(^{A,B}\): Significant difference between means of rows.

Different superscript letters: Significant difference between means of rows.

Dimisianos \textit{et al.} (2014) showed a significant increased level of IFN-γ, TNF-α, and IL-2 in sera of IFN-β responder MS patients compared to untreated patients. A similar observation was also made for IL-12 (Musabak \textit{et al.}, 2011); therefore, IL-12 might be involved in MS immunopathology, especially in pre-medicated patients of present study. It has been suggested that IL-12 is the main regulator of Th1 cell response through IFN-γ production as it is one of the CD8+ cells signals and also contributes to CD4+ cells survival (Del Vecchio \textit{et al.}, 2007). Elevated level of this cytokine was interpreted as a dysfunction of NK cells activity and imbalance of Th1/Th2 ratio. Accordingly, this cytokine might be considered as one of the markers for MS pathogenesis (Wong \textit{et al.}, 2015). The investigated IL-12 was also evaluated in terms of EDSS, and the results suggested that serum level of this cytokine might not be influenced by EDSS.
**IL12B Gene SNP at +1188 Position (rs3212227):**
The IL12B gene SNP at position +1188 was presented with two alleles (A and C) and three genotypes (AA, AC and CC). These genotypes showed deviation from HWE in MS patients, because there was a significant difference between the observed and expected genotype frequencies \( (p \leq 0.01) \), while a good agreement with HWE was observed in controls (Table 3). The results revealed that genotype frequencies of AA \( (52.2\% \text{ vs. } 60.0\%) \) and AC \( (29.9\% \text{ vs. } 40.0\%) \) showed variations between MS patients and controls, but the differences were not significant. The third genotype (CC) was observed with a frequency of 17.9\%, while none of the control subjects possessed this genotype. Such difference scored OR value of 9.23, and the associated etiological fraction (EF) was 0.16. In addition, the mutant allele (C) was also observed to have an increased frequency in patients compared to controls \( (32.8\% \text{ vs. } 20.0\% \text{; OR} = 1.96; \text{EF} = 0.16; 95\% \text{ C.I.} = 0.84 - 4.55) \). However, none of these differences in genotype and allele frequencies attended any significant level (Table 3).

Reviewing the literature, it was revealed that IL12B+1188 SNP in MS was the subject of five studies; four in Caucasians (Hall et al., 2000; van Veen et al., 2001; Forte et al., 2006; Shokrgozar et al., 2009), and one in Asians (Liu et al., 2014). Several significant and non-significant genetic associations with this SNP were reported in these studies; but the general theme was in favor of IL12B+1188 genotypes and alleles have no association with MS risk.

To clarify the role of IL12B+1188 in MS predisposition, Huang et al. (2016) performed a meta-analysis of data reported in the seven case-control studies. Although the pooled analysis showed an association between IL12B+1188 and MS in all study subjects under dominant model and allelic comparison model, in subgroup analysis based on ethnicity, they did not find an association between IL12B+1188 and MS risk in Caucasians under dominant, recessive, homozygote, and allelic comparison models, and the same finding was also recorded for the single Asian study. Accordingly, the present study shares the conclusion of these studies, and IL12B+1188 might have no influence on MS risk.

**Table 3:** Observed and expected genotype and allele frequencies of IL12B+1188 in multiple sclerosis patients and controls.

| Groups          | Genotypes | HWE \( p \) | Alleles |
|-----------------|-----------|-------------|---------|
|                 | AA | AC | CC |          | A | C |
| MS patients     | Observed | 35 | 20 | 12 | 0.01 | 90 | 44 |
| (No. = 67)      | %  | %  | %  |       | % | %  |
| (ND=1)          | 52.2 | 29.9 | 17.9 | Not estimated |
| Expected        | No. | 30.2 | 29.6 | 7.2 |       | 67.2 | 32.8 |
|                 | %  | 45.1 | 44.1 | 10.8 |       | Not estimated |
| Controls        | Observed | 12 | 8  | 0  | N.S. | 32 | 8  |
| (No. = 20)      | %  | %  | %  |       | % | %  |
| (ND=1)          | 60.0 | 40.0 | 0.0  | Not estimated |
| Expected        | No. | 12.8 | 6.4  | 0.8  |       | 80.0 | 20.0 |
|                 | %  | %  | %  |       | % | %  |
|                 | 64  | 32  | 4   | Not estimated |
| Odds Ratio (OR) | 0.73 | 0.64 | 9.23 |       | 0.51 | 1.96 |
| Etiological Fraction (EF) | -  | -  | 0.16 |       | -  | 0.16 |
| Preventive Fraction (PF) | 0.16 | 0.15 | -  |       | 0.39 | -  |
| Fisher's Exact Probability | N.S. | N.S. | N.S. |       | N.S. | N.S. |
| 95% Confidence interval (C.I.) | 0.27-1.97 | 0.23-1.76 | 0.56-152.57 |       | 0.22-1.19 | 0.84-4.55 |

HWE: Hardy-Weinberg Equilibrium; N.S.: Not significant; ND: Not determined

**Impact of IL12B+1188 SNP genotypes on IL-12 Serum Level:**
The IL12B+1188 CC genotype recorded the lowest serum level of IL-12 among MS patients \( (27.1 \pm 3.1 \text{ pg/ml}) \), but a significant difference was reached when the comparison was made with the mean of AC genotype in patients \( (35.9 \pm 2.4 \text{ pg/ml}) \). In controls, there was no significant impact of IL12B+1188 genotypes on IL-12 level (Figure 1). It was indicated that IL-12 levels are affected by some functional polymorphisms like that in the 3’ UTR region of IL12B gene (Peng et al., 2006; Gerenova et al., 2016). Nevertheless, some studies referred to the association of IL12B gene functional polymorphisms to some autoimmune diseases (Gerenova et al., 2016). Correspondingly, it was stated that polymorphism within IL12B gene may influence the responses of Th-1 cells which can be attributed to increase pathogenesis or become beneficial for some autoimmune diseases (Morahan et al., 2001).
Conclusion:
The current study indicated that AC genotype of $IL12B_{+1188}$ SNP influenced the serum level of IL-12 in a sample of MS Iraqi patients, which may contribute to the pathogenesis of MS. In addition, despite the non-significant variation in allele and genotype frequencies between MS patients and controls, CC genotype of $IL12B_{+1188}$ SNP can be of risk nine-fold in carriers as compared to none carriers, and makes it as a risk genotype for MS.

References:
1. Abramson, J.H. (2011). WINPEPI updated: computer programs for epidemiologists, and their teaching potential. *Epidemiologic Perspectives & Innovations*. 8:1.
2. Ad'hiah, A.H. (1990). Immunonogenetic studies in selected human diseases. *Ph.D. Thesis*, Department of Human Genetics, University of Newcastle upon Tyne. U.K.
3. Del Vecchio, M.; Bajetta, E.; Canova, S.; Lotze, M.T.; Wesa, A.; Parmiani, G.; and Anichini, A. (2007). Interleukin-12: Biological properties and clinical application. *Clinical Cancer Research*. 13(16): 4677-4685.
4. Dimisianos, N.; Rodi, M.; Kalavrizioti, D.; Georgiou, V.; Papathanasopoulos, P.; and Mouzaki, A. (2014). Cytokines as biomarkers of treatment response to IFN in relapsing-remitting multiple sclerosis. *Multiple Sclerosis International*. Volume (2014). Article ID (436764).
5. Forte, G.I.; Ragonese, P.; Salemi, G.; Scola, L.; Candore, G.; D’Amelio M.; Crivello, A.; Di Benedetto, N.; Nuzzo, D.; Giacalone, A.; Lio, D.; and Caruso, C. (2006). Search for genetic factors associated with susceptibility to multiple sclerosis. *Annals of the New York Academy of Sciences*. 1067:264-9.
6. Fragoso, Y.D.; Stoney, P.N.; and McCaffrey, P.J. (2014). The evidence for a beneficial role of vitamin A in multiple sclerosis. *CNS Drugs*. 28(4):291-9.
7. Fukaura, H. (2014). Environmental risk factors and gene-environment interactions for the development of multiple sclerosis. *International Journal of Neurology and Neurotherapy*. 1(1):1-3
8. Gerenova, J.; Manolova, I.; and Stanilova, S. (2016). Impact of IL-10 and IL-12B single nucleotide polymorphisms on circulating cytokine level in development of Hashimoto’s thyroiditis. *Biotechnology & Biotechnological Equipment*. 22(48):1-9.
9. Hall, M.A.; McGlinn, E.; Fischer, S.A.; Boki, K.; Middleton, D.; Kaklamani, E.; Moutsopoulos, H.; Loughran Jr., T.P.; Ollier, W.; Panayi, G.S.; and Lanchbury, E. (2000). Genetic polymorphism of IL-12p40 gene in immune–mediated disease. *Genes and Immunity*. 1:219-224.
10. Huang, J.; Yang, Y.; Zhou, F.; Liang, Z.; Kang, M.; Kuang, Y.; and Li, F. (2016). Meta-analysis of the IL23R and IL12B polymorphisms in multiple sclerosis. *International Journal of Neuroscience*. 126(3):205-212.
11. Liu, M.; Hu, X.; Wang, Y.; Chen, X.; and Wu, J.(2014). Association of IL-23 and its receptor gene single-nucleotide polymorphisms with multiple sclerosis in Chinese southern population. *International Journal of Neuroscience*. 124(12): 904-907.

12. Milo, R.and Miller, A. (2014). Revised diagnostic criteria of multiple sclerosis. *Autoimmunity Reviews*. 13(4-5):518-24.

13. Morahan, G.; Huang, D.; Ymer, S.I.; Cancilla, M.R.; Stephen, K.; Dubadghao, P.; Werther, G.; Tait, B.D.; Harrison, L.C.; Colman, P.G.(2001). Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. *Nature Genetics*. 27(2):218-21.

14. Musahak, U.; Demirkaya, S.; Genç, G.; Ilikci, R.S.; and Odabasi, Z.(2011). Serum adiponectin, TNF-α, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. *Neuroimmunomodulation*. 18(1):57-66.

15. Peng, J.C.; Bakar, S.A.; Richardson, M.M.; Jonsson, J.J.; Frazer, I.H.; Nielsen, L.K.; Morahan, G. and Thomas, R.(2006). *IL10* and *IL12B* polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS. *Immunology and Cell Biology*. 84: 227–232.

16. Shirani, A. and Tremlett, H. (2010). The effect of smoking on the symptoms and progression of multiple sclerosis: a review. *Journal of Inflammation Research*. 3:115–126.

17. Shokrgozar, M.A.; Sarial, S.; Amirzargar, A.; Shokri, F.; Rezaei, N.; Arjang, Z.; Radfar, J.; Yousefi-behzadi, M.; Sahraian, M.A.; & Lotfi, J.(2009). IL-2, IFN-γ, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis. *Journal of Clinical Immunology*. 29:747–751.

18. *Statistical* Package for Social Sciences (SPSS) for windows version 13.(2004). Lead Technologies Inc, USA.

19. van den Elsen, P.J.; van Eggermon, M.C.J.A.; Ruitenbeek, F.; Paul van der Valka, P.; Baker, D.; and Amor, S. (2014). The epigenetics of multiple sclerosis and other related disorders. *Multiple Sclerosis and Related Disorders*. 3(2): 163–175.

20. van Veen, T.; Crusius, J.B.; Schrijver, H.M.; Bouma, G.; Killestein, J.; van Winsen, L.; Salvador Peia, A.; Polman, C.H.; and Uitdehaag, B.M. (2001). Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis. *Annals of Neurology*. 50(2):275.

21. van Wanrooij, R.L.J.; Zwijsen, A.; Kraal, G.; and Bouma, G.(2012). Genetic variation in interleukin-12 related genes in immune-mediated diseases. *Journal of Autoimmunity*. 39(4):359-68.

22. Wong, N.; Nguyen, T.; Breu, E.W.; Broadley, S.; Staines, D.; and Marshall-Gradisnik, S. (2015). A comparison of cytokine profiles of chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis patients. *International Journal of Clinical Medicine*. 6:769-783.

23. Xu, M.; Mizoguchi, I.; Morishima, N.; Chiba, Y.; Mizuguchi, J.; and Yoshimoto, T.(2010). Regulation of antitumor responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. *Clinical and Developmental Immunology*. Volume (2010). Article ID (832454).

24. Zhang, L.; Fan, D.; Liu, L.; Yang, T.; Ding, N.; Hu, Y.; Cai, G.; Wang, L.; Xin, L.; Xia, Q.; Li, X.; Xu, S.; Xu, J.; and Yang, X. (2015). Association Study of *IL-12B* Polymorphisms Susceptibility with Ankylosing Spondylitis in Mainland Han Population. *PLoS One*. 10(6):1-9.